FDA Brief

Warning letters Drugs

FDA warning letter to

Vintage Chemical Inc.

High riskIssued Mar 27, 2024Posted May 14, 2024Division of Pharmaceutical Quality Operations III

FDA warned Vintage Chemical after an inspection found over-the-counter hand soap and sanitizer made on equipment shared with industrial cleaners.

What happened

FDA inspected the drug manufacturing facility in Fort Wayne, Indiana, from November 13 to 20, 2023. FDA found the company made over-the-counter antibacterial hand soap and hand sanitizer on the same equipment used for industrial detergents and degreasing products. FDA also found the company did not test each batch for potency or objectionable microorganisms before release and did not perform identity testing on incoming raw materials.

What FDA found

  1. The company made drug products on the same equipment used for industrial detergents and degreasing products, creating a risk of cross-contamination.

    21 CFR 211.42(c)
  2. The company released hand sanitizer and antibacterial hand soap without testing each batch for potency and objectionable microorganisms.

    21 CFR 211.165(a) and 211.165(b)
  3. The company did not perform identity testing on each incoming component lot and did not validate suppliers’ certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days, and it recommends a qualified consultant to audit its operations and help it meet current good manufacturing practice requirements.

Who should pay attention

  • retailers and distributors selling Vintage Chemical’s over-the-counter hand soap and sanitizer
  • brands that buy over-the-counter drug products from this contract manufacturer
  • companies using shared equipment for drugs and industrial products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk